BartDaddy
7年前
Pure Global Prepares for Release of Additional Products and add Cultivation and Extraction
TORONTO, Sept. 9, 2019 /CNW/ - Pure Global Cannabis Inc. (TSX.V: PURE; OTC: PRCNF; FRA: 1QS) ("Pure Global" or "PURE") an integrated, growth-oriented life sciences and consumer products cannabis company, through its wholly-owned subsidiary PureSinse Inc. ("PureSinse" or the "Company"), a Health Canada licensed producer under The Cannabis Act, is pleased to announce that it has received approval from Health Canada for its most recent license amendment request allowing for the sale of cannabis oil products, including high cannabidiol ("CBD") and premium craft cultivars that will become available soon for medical and legal adult patients.
This licensing will allow the Company to significantly expand its product offerings to the medical and consumer markets with oils and post-derivative cannabis products, which are seeing growing demand. Oils and post-derivatives will be deployed throughout the Company's brand ecosystem, especially as edibles and post-derivative products regulations come into being this fall. This will enable the company to significantly expand consumer sales through higher margin products.
The Company already has prepared oils formulations, as well as purification, processing, and packaging equipment in place for this next phase of operations. It has the capacity to purify, formulate, and process 10 liters of oil per day, 10,000 capsules per hour, 10,000 vape cartridges per hour, and 2,000 oils bottles per hour. With Health Canada approval for oil sales, the Company can release its line of extraction-based products which will soon be available through its PureSinse Medical eCommerce site, as well as legal retail cannabis stores across Canada. Pure Global had already expanded production capabilities, anticipating license approval, to include in-house production of medicated topicals, creams, gels, balms, lotions, tinctures, sprays, vape pens, oils bottles, and gel capsules.
This licensing also clears the path for Health Canada approvals for Phase 2 cultivation and extraction, for which the Company has already submitted its readiness package and is in final stages of approvals. With over 80 genetics to choose from, the company is ready to begin vertically farmed cultivation and scaled extraction for its branded and for white labeled products.
"This is an important milestone in our company's history which will significantly expand our product offerings for the medical and legal adult channels. We will be able to sell high-margin oils and post-derivative products across all of our premium brands and will be one of only and handful of Licensed Producers to be able to do so. Over 50% of medical patients are looking for post-derivative products as well as those in our target consumer markets, which we will now be much better able to serve," commented Malay Panchal, President and CEO of Pure Global.
About Pure Global Cannabis
Pure Global Cannabis Inc. is an innovation-based cannabis company led by experienced pharma, biotechnology, horticultural, and consumer packaged goods (CPG) experts. The company's wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Cannabis Act. The company's Brampton campus houses facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. Pure Global will produce branded and white-labeled cannabis products for the medical, pharmaceutical, wellness, health & beauty, natural health, food & beverage, craft, and recreational legal markets with uniquely formulated and purified concentrates and dried flower. The company is using the Canadian market as a springboard to develop and manufacture euGMP-compliant premium quality cannabis products for international sale and distribution with a goal to become one of the most trusted premium international cannabis brands.
FORWARD-LOOKING STATEMENTS
This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global's future plans and intentions. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
To register to Pure Global's mailing list, please visit www.pureglobal.com. Follow @pureglobalcanna on Twitter and Facebook and @pureglobalcannabis on Instagram.
SOURCE Pure Global Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2019/10/c5619.html
/CONTACT:
Stephen Pynn, VP Corporate Development, Telephone: 1-866-840-PURE (7873) ext. 111, E-mail: stephen@pureglobal.com; Malay (Mel) Panchal, President & CEO, Telephone: 1-866-840-PURE (7873), E-mail: info@pureglobal.com
Copyright CNW Group 2019
ragi
7年前
This company is under the radar. It could potentially have a huge run once traders recognize their position in the cannabis market: Pure Global Cannabis Inc. (TSX.V:PURE;OTC: PRCNF; FRA:1QS) is an innovation-based cannabis Company led by experienced pharma, biotechnology, horticultural, and consumer packaged goods (CPG) experts. The Company's wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Cannabis Act. The Company's Brampton campus houses facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. PURE will produce branded and white-labeled cannabis products for the medical, pharmaceutical, wellness, health & beauty, natural health, food & beverage, and recreational legal markets with uniquely formulated and purified concentrates.
JohnCM
8年前
PURE GLOBAL CANNABIS ANNOUNCES ADDITIONAL BULK PURCHASE ORDER FROM
SUPREME CANNABIS
PURCHASE SECURES SUFFICIENT PRODUCT QUANTITIES FOR Q4 MARKET LAUNCH
FOR IMMEDIATE RELEASE
TORONTO, ONTARIO – August 14, 2018 – Pure Global Cannabis Inc. (TSX.V:PURE; OTC:
PRCNF) (the “Company” or “Pure Global” or “PURE”), a vertically-integrated, growth-oriented life
sciences cannabis company, is pleased to announce that its wholly-owned subsidiary, PureSinse Inc.
("PureSinse"), has agreed to purchase from The Supreme Cannabis Company, Inc. ("Supreme") (TSXV:
FIRE) an additional 210kg of medical cannabis for resale.
PURE’s President & CEO Malay Panchal stated: "We are very pleased to secure a significant volume of
additional product that meets our standards of quality from our great partner, Supreme. With this order,
our company will have ample cannabis inventory to go to market within the next few months, in addition
to enabling us to launch several clinical studies in specific therapeutic areas.”
PureSinse is one of the first Licensed Producers to receive a cultivation license prior to building out
growing systems. Instead, the company focused its initial efforts and resources on R&D, and establishing
sales, IT, and operational systems. This uniquely positions the company to generate sales more quickly
and with less upfront capital outlay than its peers.
PURE is positioning itself to be a dominant player in the cannabis pharma, health & wellness, and
consumer goods sectors by committing itself to creating unique cannabinoid-based delivery systems and
formulations with sustainable packaging. The company will soon begin selling dried flower and cannabis
oils, followed by capsules, sublingual sprays, edibles, vape pens, and ultimately a full range of premium
quality CBD and cannabis-based consumer goods for medical and adult-legal sales. The company is also
on track to obtain EU Good Manufacturing Practice (GMP) and ISO certifications in early 2019 for
expanding its sales to international markets.
JohnCM
8年前
Pure Global Cannabis Completes $10 Million Financing
Sep. 17, 2018, 04:50 PM
TORONTO, Sept. 17, 2018 /CNW/ - Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF) (the "Company" or "Pure Global"), a vertically integrated growth-oriented life sciences cannabis company, is pleased to announce, further to its news release dated August 15, 2018, that it has completed a brokered private placement offering of convertible debenture units (the "Convertible Debenture Units") of the Company, with a syndicate of investment dealers led by Eventus Capital Corp. and including PI Financial Corp., for gross proceeds of $10 million (the "Offering").
Each Convertible Debenture Unit shall be comprised of $1,000 aggregate principal amount of 8% senior secured convertible debentures of Pure Global (the "Convertible Debentures") and 1,429 warrants (the "Warrants"). The Convertible Debentures mature 36 months from the closing date of the Offering (the "Closing Date") and, at any time following the date that is four months and one day following the Closing Date, will be convertible at the option of the holder into common shares of Pure Global at a conversion price $0.35 per share (the "Conversion Price").
Furthermore, beginning on the date that is four months and one day following the Closing Date, the Company may force the conversion of all of the principal amount of the then outstanding Convertible Debentures at the Conversion Price on 30 days' prior written notice should the daily volume weighted average trading price of the Pure Global common shares be greater than $0.65 for any 10 consecutive trading days. Each Warrant shall entitle the holder to acquire one common share of Pure Global at a price of $0.45 per share for a period of 36 months following the Closing Date.
The net proceeds of the Offering are intended to be used primarily to fund the acquisition of a 60% interest (the "Acquisition") in Sativa Nativa S.A.S. ("Sativa Nativa"), a Colombian subsidiary of Avicanna Inc. ("Avicanna"). Completion of the Acquisition is subject to customary conditions for an investment of this nature, including satisfactory due diligence and the receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, and consents in Colombia and Canada. If the Acquisition is not completed, the Company intends to use the net proceeds of the Offering to fund alternate acquisition opportunities, organic growth initiatives and for general working capital purposes.
All securities issued in connection with the Offering are subject to a four month hold period expiring January 18, 2019.
About Pure Global Cannabis
Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF) is a vertically-integrated, growth-oriented life sciences cannabis company led by experienced pharma-industry, horticultural, consumer packaged goods (CPG), and supply chain experts. The Company's wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR) focused on producing cannabis products for medical, wellness, health & beauty, natural health, and future legal adult use markets.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Hedgefundanalyst
7年前
MADDSTACKER
7年前
$BL$
7年前
メールアドレスで登録
